NCT06576024View on ClinicalTrials.gov

Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People

PHASE4RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

October 19, 2024

Study Completion Date

December 20, 2024

Conditions
Hepatitis AImmunodeficiencyHIV Infections
Interventions
BIOLOGICAL

2 doses of HAV

Participants will receive two doses of HAV with a 6-month interval

BIOLOGICAL

At least one dose of HAV

Participants will receive the first dose of HAV and will receive the second dose with a 6 -month interval voluntarily.

Trial Locations (1)

Unknown

RECRUITING

Liuzhou People's Hospital, Liuzhou

All Listed Sponsors
collaborator

Sinovac Biotech Co., Ltd

INDUSTRY

lead

LiuZhou People's Hospital

OTHER